We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Combination Hypertension Drug Development
FDA Issues Guidance on Combination Hypertension Drug Development
Drug sponsors can prove the effectiveness of combination drugs for treatment of hypertension with trials that test the highest approved dosage rather than trials with multiple doses, the FDA said in new draft guidance for developing such products.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor